New Atlas

Next-gen vaccine prevents up to 88% of multiple aggressive cancers

A next-generation cancer vaccine has shown stunning results in mice, preventing up to 88% of aggressive and ...

GSK's three-drug inhaler wins U.S. nod for use in asthma patients

GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...
PharmiWeb

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of CSCC

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.
Oncology Nurse Advisor

Subcutaneous Isatuximab Effective Across All Lines of Therapy in RRMM

Researchers sought to determine whether subcutaneous isatuximab would be an effective treatment for patients with RRMM.
Arizona Daily Star

Conservative activist Charlie Kirk dies after being shot at Utah college event

OREM, Utah — Charlie Kirk, a conservative activist and close ally of President Donald Trump who played an influential role in rallying young Republican voters, was shot and killed Wednesday at a Utah ...